AUG 14, 2026 · PHASE 3 TRIAL
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
ClinicalTrials.gov
This is a Phase 3 trial registration with no results posted; it describes a planned study of investigational therapy in advanced NSCLC, currently recruiting.
Reported
Planned sample size1160
Primary outcome measure 1Overall survival (OS), up to approximately…
Primary outcome measure 2Progression-free survival (PFS), up to appr…